Global study for Alzheimer's vaccine


Friday, 22 September, 2017


Global study for Alzheimer's vaccine

A global study is testing a vaccine and oral medication to prevent or delay Alzheimer’s in older adults who have an increased risk of the disease. If successful, the vaccine would stop Alzheimer’s years before it begins, halting a disease that affects 47 million people worldwide.

“One of the challenges in developing new medications for Alzheimer’s is that researchers tend to test medications on people with more advanced Alzheimer’s, and the medications are simply not proving to be effective,” said the study’s lead investigator at the Keck School, Dr Lon Schneider. “By intervening 10 to 12 years before Alzheimer’s manifests, we may be able to stop it before it begins or delay the symptoms.”

Adults 60 to 75 years of age with normal cognition who are interested in participating must undergo genetic testing for the apolipoprotein e4 (APOE4) gene, which is associated with an increased risk of developing Alzheimer’s.

About half of people with Alzheimer’s disease carry the APOE4 gene, which can be inherited from either parent, Schneider said. About 25% of the population carries one copy of the APOE4 gene, and about 2% to 3% of the population carries two copies, having received one from each parent. To qualify for the study, participants must have two copies of the gene.

Qualifying participants may be randomised to either a vaccine, oral medication, placebo vaccine or placebo oral medication. Both the vaccine and oral medication target amyloid beta — the main component in amyloid plaques in the brain and a culprit in Alzheimer’s — in two different ways: the vaccine helps the body develop antibodies against amyloid beta, while the oral medication blocks an enzyme that creates amyloid beta. Participants may receive the study medications for five to eight years.

“If we are able to show that the vaccine or oral medication is effective at delaying Alzheimer’s among people at higher risk, then this would strongly imply that we are on the right track for developing treatments,” Schneider said. “If we can delay the onset of Alzheimer’s by five years, for example, the incidence of the illness would drop by half. It would also give individuals five more years without symptoms of the illness.”

Should the vaccine or oral medication prove to be effective in people with two copies of the APOE4 gene, then it would likely also be effective for other people at risk for Alzheimer’s, according to Schneider.

Almost 90 institutions in North America, Europe and Australia are participating in the Generation Study.

Image credit: ©stock.adobe.com/au/freshidea

Related News

Beyond Blue launches 24/7 pandemic support service

Beyond Blue has partnered with Accenture and Medibank to develop a 24/7 Coronavirus Mental...

PI Therapy as effective as CBT in depression/anxiety

A treatment for depression and anxiety developed at Murdoch University has been shown to be as...

Interpreter boost reduces patient self-discharge

A study conducted at Royal Darwin Hospital has found that increased use of Aboriginal...


  • All content Copyright © 2020 Westwick-Farrow Pty Ltd